Peak Study: A Phase 3, Randomized, Open-label Multicenter Clinical Study of Bezuclastinib (CGT9486) and Sunitinib Combination Versus Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)
American Society of Clinical Oncology Annual Meeting